Mitomycin c intravesical therapy in noninvasive bladder cancer after failure on thiotepa

Brian F. Issell, George R. Prout, Mark S. Soloway, Kenneth B. Cummings, George Brannen, Ralph Veenema, Malachi Flanagan, Norman L. Block, Jack L. Summers, Elizabeth A. Levin, M. Dianne Defuria

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


Mitomycin C 40 mg in 40 ml water was administered intravesically every week for 8 consecutive weeks to 60 patients with superficial bladder cancer. All patients had failed treatment with intravesical thiotepa and had evaluable disease. An objective response of 50% or greater reduction in measured tumor mucosal involvement was obtained in 68% of patients. Forty-two percent of the patients achieved a complete response, and this included 50% of patients with Grade III disease and 70% of patients with a T1 tumor. Median response duration in complete responders was 12.2 months with a range of 3.5 to 24.3+ months. Fifty-five percent of patients are still responding. Therapy was generally well tolerated, and in contrast to thiotepa, myelosuppression was not the dose-limiting effect. One third of all patients experienced symptoms of local irritation, and skin reactions were seen in 12% of patients.

Original languageEnglish (US)
Pages (from-to)1025-1028
Number of pages4
Issue number5
StatePublished - Mar 1 1984
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Mitomycin c intravesical therapy in noninvasive bladder cancer after failure on thiotepa'. Together they form a unique fingerprint.

Cite this